Medistim delivers strong Q2 growth with 32% margins

Medistim ASA reported Q2 sales revenue up 16.7% to MNOK 169.1, with half-year revenue rising 25.8% to MNOK 350.6. Operating profit surged 31.2% in Q2 to MNOK 54.1, achieving a 32.0% margin.

The Americas and Asia-Pacific regions drove growth with currency-neutral increases of 32.9% and 22.9% respectively in Q2. The company maintained cash of MNOK 96.4 after paying dividends of NOK 6.00 per share totaling MNOK 109.9.